Published on: December 4th, 2019 • Duration: 20 minutes
Scott Williams, portfolio manager for Fiftyone Capital, sits down to explain why he thinks Paradigm Biopharmaceuticals could be a hundred-bagger. The company’s repurposed pre-trial drug has already treated thousands of patients in Australia and is currently being tested on retired NFL players. Williams articulates his investment thesis to Real Vision’s Justine Underhill in today’s Trade Ideas. Filmed on December 3, 2019 in New York.